COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.


           Research Publications, Peer-Reviewed

  1. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001; 166(11):6812-9.
  2. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001; 34(1):89-100.
  3. Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology. 2001; 34(5):953-63.
  4. Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002; 82(3):323-33.
  5. Stefanovic B, Schnabl B, Brenner DA. Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem. 2002; 277(20):18229-37.
  6. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003; 37(3):653-64.
  7. Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol. 2003; 39(1):38-46.
  8. Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol Cell Biol. 2004; 24(4):1758-68.
  9. Mühlbauer M, Weiss TS, Thasler WE, Gelbmann CM, Schnabl B, Schölmerich J, Hellerbrand C. LPS-mediated NFkappaB activation varies between activated human hepatic stellate cells from different donors. Biochem Biophys Res Commun. 2004; 325(1):191-7.
  10. Schnabl B, Choi YH, Hagedorn CH, Bataller R. DNA microarrays and data mining to study hepatic fibrosis. Methods Mol Med. 2005; 117:359-69.
  11. Hu K, Fink M, Froh M, Gäbele E, Hellerbrand C, Mühlbauer M, Wiest R, Schölmerich J, Schnabl B. Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y. Biochim Biophys Acta. 2005; 1729(1):14-23.
  12. Schnabl B, Hu K, Mühlbauer M, Hellerbrand C, Stefanovic B, Brenner DA, Schölmerich J. Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. Biochem Biophys Res Commun. 2005; 335(1):87-96.
  13. Meiler C, Muhlbauer M, Johann M, Hartmann A, Schnabl B, Wodarz N, Schmitz G, Scholmerich J, Hellerbrand C. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol. 2005; 11(38):6031-7.
  14. Wiest R, Jurzik L, Moleda L, Froh M, Schnabl B, von Hörsten S, Schölmerich J, Straub RH. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol. 2006; 44(3):512-9.
  15. Tacke F, Trautwein C, Yagmur E, Hellerbrand C, Wiest R, Brenner DA, Schnabl B. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol. 2007; 22(8):1256-64.
  16. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007; 204(8):1891-900.
  17. Tacke F, Gäbele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, Luedde T, Manns MP, Trautwein C, Brenner DA, Schölmerich J, Schnabl B. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007; 52(12):3404-15.
  18. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, Schnabl B, DeMatteo RP, Pamer EG. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008; 455(7214):804-7.
  19. Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gäbele E, Hellerbrand C, Falk W. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun. 2008; 375(2):210-4.
  20. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008; 48(5):1420-9.
  21. Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, Wiest R, Schölmerich J, Obermeier F, Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun. 2008; 376(2):271-6.
  22. De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology. 2008; 48(6):2016-26.
  23. Brandl K, Rutschmann S, Li X, Du X, Xiao N, Schnabl B, Brenner DA, Beutler B. Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc Natl Acad Sci U S A. 2009; 106(9):3300-5.
  24. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA. Antiapoptotic Effect of c-Jun N-terminal Kinase-1 through Mcl-1 Stabilization in TNF-induced Hepatocyte Apoptosis. Gastroenterology. 2009; 136(4):1423-34.
  25. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, De Minicis S, Österreicher CH, Schnabl B, Seki E, Brenner DA. JNK1 Derived from Hematopoietic Cells Mediates Progression from Diet-Induced Hepatic Steatosis to Steatohepatitis and Fibrosis in Mice. Gastroenterology. 2009; 137(4):1467-1477.
  26. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis via induction of interleukin-1β in mice. Gastroenterology. 2010; 139(1):323-34.
  27. Tacke F, Zimmermann HW, Trautwein C, Schnabl B. CXCL5 plasma levels are decreased in patients with chronic liver disease. J Gastroenterol Hepatol. 2011; 26(3):523-9.
  28. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric Dysbiosis Associated with a Mouse Model of Alcoholic Liver Disease. Hepatology. 2011; 53(1):96-105.
  29. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, Kisseleva T, Brenner DA. The nicotinamide adenine dinucleotide phosphate oxidase homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 2011; 53(5):1730-41.
  30. Siggs OM, Schnabl B, Webb B, Beutler B. X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C. Proc Natl Acad Sci U S A. 2011; 108(19):7890-5.
  31. Schnabl B, Valletta D, Kirovski G, Hellerbrand C. Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol. 2011; 91(3):695-701.
  32. Schnabl B, Czech B, Valletta D, Weiss TS, Kirovski G, Hellerbrand C. Increased expression of Zinc finger protein 267 in non-alcoholic fatty liver disease. Int J Clin Exp Pathol. 2011; 4(7):661-6.
  33. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012; 56:1283–92.
  34. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A. 2012; 109(21):E1369-76.
  35. Brandl K, Tomisato W, Li X, Neppl C, Pirie E, Falk W, Xia Y, Moresco EY, Baccala R, Theofilopoulos AN, Schnabl B, Beutler B. Yip1 domain family, member 6 (Yipf6) mutation induces spontaneous intestinal inflammation in mice. Proc Natl Acad Sci U S A. 2012;109(31):12650-5.
  36. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-Like Receptor 2-mediated intestinal injury and enteric Tumor Necrosis Factor Receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012; 143(5):1330-1340.
  37. Grivennikov S, Wang K, Mucida D, Stewart AC, Schnabl B, Jauch D, Taniguchi K, Yu G, Osterreicher C, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-associated barrier deterioration drives IL-23 dependent inflammation and tumor growth. Nature. 2012; 491(7423):254-8.
  38. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 2013; 58(1):108-19.
  39. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterology Research and Practice. 2013; 2013:498296.
  40. Wang L, Hartmann P, Haimerl M, Bathena SP, Sjöwall C, Almer S, Alnouti Y, Hofmann AF, and Schnabl B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J Hepatol. 2014; 60(6):1259-67.
  41. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13(3):561-568.
  42. Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates TNFRI and mediates alcoholic liver disease in mice. Hepatology. 2015; 61(3):883-94.
  43. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nature Medicine. 2015; 21(2):159-165.
  44. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015; 29(3):1043-55.
  45. Wang L, Llorente C, Hartmann P, Yang A, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods. 2015; 421:44-53.
  46. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015;148(1):203-214.
  47. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13(8):1513-1520.
  48. Chen P, Miyamoto Y, Mazagova M, Lee K, Eckmann L, Schnabl B. Microbiota protects mice against acute alcohol-induced liver injury. Alcohol Clin Exp Res. 2015; 39(12):2313-23.
  49. Schnabl B, Farshchi-Heydari S, Loomba R, Mattrey RF, Hoh CK, Sirlin CB, Brenner DA, Behling C, Vera DR. Staging of Fibrosis in Experimental Non-Alcoholic Steatohepatitis by Quantitative Molecular Imaging in Rat Models. Nuclear Medicine and Biology. 2016;43(2):179-87.
  50. Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol. 2016;310(5):G310-22.
  51. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect Against Alcoholic Steatohepatitis by Reducing Mucosa-associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016; 19(2):227–239.
  52. Inamine T, Yang A, Wang L, Lee KC, Llorente C, Schnabl B. Genetic loss of immunoglobulin A does not influence development of alcoholic steatohepatitis in mice. Alcohol Clin Exp Res. 2016; 40(12):2604-2613.
  53. Patel NS, Hooker J, Gonzalez M, Bhatt A, Nguyen P, Ramirez K, Richards L, Rizo E, Hernandez C, Kisseleva T, Schnabl B, Brenner D, Sirlin CB, Loomba R. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016; S1542-3565(16)30861-8.
  54. Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE. Extracellular vesicles released by hepatocytes from gastric infusion model of ALD contain a miRNA barcode that can be detected in blood. Hepatology. 2017; 65(2):475-490.
  55. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.
  56. Yang A, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, KoyamaY, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen C, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017; 127(7):2829-2841.
  57. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017; 8(1):837.
  58. Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, Huang K, Yang L, Hou X. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018; 175(3):469-484.
  59. Ouyang X, Han S, Zhang J, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Caii S, Schnabl B, Hoque R, Chen Y, Yang W, Garcia Martinez I, Wang  F, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2 Promoted HIF-1a Transactivation in Steatohepatitis. Cell Metab. 2018; 27(2):339-350. PMID: 29414684.
  60. Hartmann H, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. Modulation of the intestinal bile acid–FXR–FGF15 axis improves alcoholic liver disease in mice. Hepatology. 2018; 67(6):2150-2166. 
  61. Khanova E, Wang W, Yan R, Chen Y, French S. W, Llorente C, Pan S. Q, Yang Q, Li Y, Lazaro R, Wu R, Ansong C, Smith R. D, Bataller R, Morgan T, Schnabl B, Tsukamoto H. Pyroptosis by Caspase11/4-Gasdermin-D Pathway in Alcoholic Hepatitis. Hepatology. 2018; 67(5):1737-1753.
  62.  Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal Reg3 lectins for Non-Alcoholic Steatohepatitis. Hepatology Commun. 2018; 2(4):393-406.
  63. Gong S, Lan T, Zeng L, Luo H, Yang X, Li N, Chen X, Liu Z, Li R, Win S, Liu S, Zhou H, Schnabl B, Jiang Y, Kaplowitz, N, Chen P. Gut microbiota functions in diurnal variation of acetaminophen induced acute liver injury in mice. J Hepatol. 2018; 69(1):51-59.
  64. Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E,  Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R for the Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018; 68(3): 918-932.   
  65. Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, DePaoli AM, Loomba R, Mehal WZ, Fouts DE, Lucey MR, Bosques-Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna EC, Abraldes JG, Brown Jr RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Stärkel P, Ho SB, Bataller R, Schnabl B. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018; 69(2):396-405.
  66. Chen Y, Ouyang X, Hoque R, Garcia-Martinez I, Massey V, Schnabl B, Bataller R, Mehal WZ. B-hydroxybutyrate protects from alcoholic hepatitis via a Hcar2-cAMP dependent pathway. J Hepatol. 2018; 69(3):687-696.
  67. Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin XJ, Wong J, Ding S, Seki E, Schnabl B, Hevener AL, Greenberg HB, Kisseleva T, Karin M. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature. 2018; 560(7717):198-203.
  68. Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther. 2019; 49(2):183-193.
  69. Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, Stärkel P, Ho SB, Gao B, Fiehn O, Emond P, Sokol H, van Pijkeren JP, Schnabl B. Bacteria Engineered to Produce IL22 in Intestine Induce Expression of REG3G to Reduce Ethanol-induced Liver Disease in Mice. Gut. 2019; 68(8):1504-1515.
  70. Gong S, Yan Z, Liu1 Z, Niu M, Fang H, Li N, Huang C, Li L, Chen G, Luo H, Chen X, Zhou H, Hu J, Yang W, Huang Q, Schnabl B, Chang P, Billiar TR, Jiang Y, Chen P. Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice. Hepatology. 2019; 69(4):1751-1767.
  71. Lee KC, Chen P, Maricic I, Inamine T, Hu J, Gong S, Sun JC, Dasgupta S, Lin H, Lin Y, Loomba R, Stärkel P, Kumar V, Schnabl B. Intestinal iNKT Cells Migrate to Liver and Contribute to Hepatocyte Apoptosis During Alcoholic Liver Disease. Am J Physiol Gastrointest Liver Physiol. 2019; 316(5): G585-G597.
  72. Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, He M, Waizenegger W, Gasser E, Schnabl B, Atkins AR, Yu RT, Knight R, Liddle C, Downes M, Evans RM. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019;176(5):1098-1112.
  73. Gao B, Lang S, Duan Y, Wang Y, Shawcross DL, Louvet A, Mathurin P, Ho SB, Stärkel P, Schnabl B. Serum and fecal oxylipins in patients with alcohol-related liver disease. Dig Dis Sci. 2019; 64(7):1878-1892. PMCID: PMC6588282.
  74. Stärkel P, Schnabl B, Leclercq S, Komuta M, Bataller R, Argemi J, Palma E, Chokshi S, Hellerbrand C, Maccioni L, Lanthier N, Leclercq I. Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis. Hepatology Commun. 2019; 3(7):867-882. PMCID: PMC6601428.
  75. Wang L, Mazagova M, Pan C, Yang S, Brandl K, Liu J, Reilly SM, Wang Y, Miao Z, Loomba R, Lu N, Guo Q, Liu J, Yu RT, Downes M, Evans RM, Brenner DA, Saltiel AR, Beutler B, Schnabl B. YIPF6 Controls Sorting of FGF21 Into COPII Vesicles and Promotes Obesity. Proc Natl Acad Sci U S A. 2019; 116(30):15184-15193. PMCID: PMC6660779.
  76. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, van der Donk WA, Young R, Lawley TD, Stärkel P, Pride D, Fouts DE, Schnabl B. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature.2019, 575(7783):505-511. PMCID: PMC6872939.
  77. Bluemel S, Wang L, Kuelbs C, Moncera K, Torralba M, Singh H, Fouts DE, Schnabl B. Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes. 2020; 11(3):265-275. PMCID: PMC7524386.
  78. Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, Brown RS Jr., Vargas V, Altamirano J, Caballería J, Shawcross D, Lucey MR,  Louvet A, Mathurin P, Garcia-Tsao G, Ho SB, Tu XM, Bataller R, Stärkel P, Fouts DE, Schnabl B.   Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 2020; 71(2):522-538. PMCID: PMC6925657.
  79. Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, Liu J, Mogavero S, Bosques-Padilla F, Abraldes JG, Vargas V, Tu XM, Yang L, Hou X, Hube B, Stärkel P, Schnabl B. The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease. J Hepatol. 2020; 72(3):391-400. PMCID: PMC7031049.
  80. Furuya S, Argemi J, Uehara T,  Katou Y, Fouts DE, Schnabl B, Dubuquoy L, Belorkar A, Vadigepalli R, Kono H, Bataller R, Rusyn I. A novel mouse model of acute-on-chronic cholestatic alcoholic liver disease: A systems biology comparison with human alcoholic hepatitis. Alcohol Clin Exp Res. 2020; 44(1):87-101. PMCID: PMC6980964.
  81. Lang S, Demir M, Duan Y, Martin A, Schnabl B. Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis. Liver International. 2020; 40(4):860-865. PMID: 31943701.
  82. Bajic D, Niemann A, Hillmer AK, Mejias-Luque R, Bluemel S, Docampo M, Funk MC, Tonin E, Boutros M, Schnabl B, Busch DH, Miki T, Schmid RM, van den Brink MRM, Gerhard M, Stein-Thoeringer CK. Gut microbiota derived propionate regulates the expression of Reg3 mucosal lectins and ameliorates experimental colitis in mice. J Crohns and Colitis. 2020; accepted. PMID: 32227170.
  83. Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Liu J, Krawczyk M, Nowag A, Kretzschmar A, Herweg J, Schnabl B, Tu XM, Lammert F, Goeser T, Tacke F, Heinzer K, Kasper P, Steffen HM, Demir M. High protein intake is associated with histological disease activity in patients with NAFLD. Hepatology Commun. 2020; 4(5):681-695. PMCID: PMC7193126.
  84. Marrero I, Maricic I, Morgan TR, Stolz AA, Schnabl B, Liu ZX, Tsukamoto H, Kumar V. Differential activation of unconventional T cells, including iNKT cells, in alcohol-related liver disease. Alcohol Clin Exp Res. 2020; 44(5):1061-1074. PMCID: PMC7211132.
  85. Gao B, Emami A, Zhou R, Lang S, Duan Y, Wang Y, Jiang L, Loomba R, Brenner DA, Stärkel P, Schnabl B. Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. Front Physiol. 2020; 11:370. PMCID: PMC7193112.
  86. Gao B, Duan Y, Lang S, Barupal D, Wu TC, Valdiviez L, Roberts B, Choy YY, Shen T, Byram G, Zhang Y, Fan S, Wancewicz B, Shao Y, Vervier K, Wang Y, Zhou R, Jiang L, Nath S, Loomba R, Abraldes JG, Bataller R, Tu XM, Stärkel P, Lawley TD, Fiehn O, Schnabl B. Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in alcoholic hepatitis patients. Hepatology Commun. 2020; 4(8):1168-1182. PMCID: PMC7395072.
  87. Chu H, Jiang L, Gao B, Gautam N, Alamoudi JA, Lang S, Wang Y, Duan Y, Alnouti Y, Cable EE, Schnabl B. The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Transl Res. 2020: S1931-5244(20)30143-2. PMID: 32553670.
  88. Maccioni L, Gao B, Leclercq S, Pirlot B, Horsmans Y, De Timary P, Leclercq I, Fouts D, Schnabl B, Stärkel P. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes. 2020; 12(1):1782157. PMCID: PMC7524402.
  89. Lang S, Fairfied B, Gao B, Duan Y, Zhang X, Fouts DE, Schnabl B. Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes. 2020; 12(1):1785251. PMCID: PMC7524371.
  90. Bluemel S, Wang Y, Lee S, Schnabl B. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World J Gastroenterol. 2020; 26(33):4933-4944. PMCID: PMC7476178.
  91. Zhou R, Llorente C, Cao J, Gao B, Duan Y, Jiang L, Wang Y, Kumar V, Stärkel P, Bode L, Fan X, Schnabl B. Deficiency of Intestinal α1-2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice. Alcohol Clin Exp Res. 2020; 44(9):1842-1851. PMID: 32628772. PMCID: PMC7808344.
  92. Jiang L, Chu H, Gao B, Lang S, Wang Y, Duan Y, Schnabl B. Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. Dig Dis Sci. 2020; 65(12):3592-3604. PMCID: PMC7669632.
  93. Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020; 159(5):1839-1852. PMID: 32652145. PMCID pending.
  94. Chu H, Bai T, Chen L, Hu L, Xiao L, Yao L, Zhu R, Niu X, Li Z, Zhang L, Han C, Song S, He Q, Zhao Y, Zhu Q, Chen H, Schnabl B, Yang L, Hou X. Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. Front Med (Lausanne). 2020; 20;7:584342. PMCID: PMC7606271.
  95. Chu H, Li J, Yan J, Bai T, Schnabl B, Zou L, Yang L, Hou X. Persistent SARS-CoV-2 RNA Positive in Feces but Negative in Breastmilk: A Case Report of COVID-19 in a Breastfeeding Patient. Front Med (Lausanne). 2020; 7:562700. PMCID: PMC7738631.
  96. Wang Z, Wang Y, Bradbury N, Gonzales Bravo C, Schnabl B, Di Nardo A. Skin wound closure delay in metabolic syndrome correlates with SCF deficiency in keratinocytes. Sci Rep. 2020; 10(1):21732. PMCID: PMC7728784.
  97. Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, Schwanemann LK, Ventura-Cots M, Bataller R, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Kisseleva T, Brenner DA, Tu XM, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal virome in patients with alcoholic hepatitis. Hepatology. 2020; 72(6):2182-2196. PMCID: PMC8159727.
  98. Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown Z, Wabitsch S, Thovarai V, Fu J, Feng D, Ruf B, Cui L, Subramanyam V, Frank KM, Wang S, Kleiner DE, Ritz T, Rupp C, Gao B, Longerich T, Wang XW, Korangy F, Kroemer A, Schnabl B, Trinchieri G, Greten TF. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discovery. 2021; 11(5):1248-1267. PMCID: PMC8102309.
  99. Gao B, Zhang X, Schnabl B. Fungi-bacteria correlation in alcoholic hepatitis patients. Toxins. 2021; 13(2):143. PMCID: PMC8102309.
  100. Zhou R, Llorente C, Cao J, Zaramela LS, Zeng S, Gao B, Li S, Welch RD, Huang FQ, Qi LW,  Pan C, Huang Y, Zhou P, Beussen I, Zhang Y, Bryam G, Fiehn O, Wang L, Liu EH, Yu RT, Downes M, Evans RM, Goglin K, Fouts DE, Brenner DA, Bode L, Fan X, Zengler K, Schnabl B. Intestinal α1-2-fucosylation contributes to obesity and steatohepatitis in mice. Cell Mol Gastroenterol Hepatol. 2021; 12(1):293-320. PMCID: PMC8166943.
  101. Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, Dhanda A, Arrese M, McCune CA, Rowe IA, Schnabl B, Mathurin P, Shawcross D, Abraldes JJ, Lucey MR, Garcia-Tsao G, Verna E, Brown RS Jr, Bosques-Padilla F, Vargas V, Louvet A, Holt AP, Bataller R. Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients with Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2021; in press. PMID: 33516950.
  102. Gao B, Argemi J, Bataller R, Schnabl B. Serum acylcarnitines associated with high short-term mortality in patients with alcoholic hepatitis. Biomolecules. 2021; accepted.
  103. Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Independent associations between gut microbiota composition, diet, PNPLA3 polymorphism and clinical parameters with liver histology features in non-alcoholic fatty liver disease. Liver Int. 2021; accepted.
  104. Ganguly S, Muench GA, Shang L, Rosenthal SB, Rahman G, Wang R, Wang Y, Kwon HC, Diomino AM, Kisseleva T, Soorosh P, Hosseini M, Knight R, Schnabl B, Brenner DA, Dhar D. Non-alcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. Cell Mol Gastroenterol Hepatol. 2021; accepted.
  105. Liu J,  Zhang X, Chen T, Wu TC, Tu L, Lingjing J, Lang S, Liu L, Natarajan I, Kosciolek T, Morton J, Nguyen TT,  Schnabl B, Knight R, Feng C, Zhong Y, Tu X. Semiparametric Model for Between-Subject Attributes: Applications to Beta-diversity of Microbiome Data. Biometrics. 2021; accepted.
  106. Hsieh YC, Lee KC, Lei HJ, Lan KH, Huo TL, Lin YT, Chan CC, Schnabl B, Huang YH, Hou MC, Lin HC.  (Pro)renin Receptor Knockdown Attenuates Liver Fibrosis through Inactivation of ERK/TGF-β1/SMAD3 Pathway. Cell Mol Gastroenterol Hepatol. 2021; accepted.
  107. Cabré N, Duan Y, Llorente C, Conrad M, Stern P, Yamashita D, Schnabl B. Colesevelam reduces ethanol-induced liver steatosis in humanized gnotobiotic mice. Cells. 2021; accepted.
  108. Hartmann P, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, Bondarevae M, Kruglove A, Fouts DE, Stärkel P, Schnabl B. Dynamic changes of the fungal microbiome in alcohol use disorder. Frontiers in Physiology. 2021; accepted. 

    Reviews, Editorials and Conference Summaries, peer-reviewed                      

  109. Schnabl B, Scholten D, Brenner DA. What is the potential role of antifibrotic agents for the treatment of liver disease? Nat Clin Pract Gastroenterol Hepatol. 2008; 5(9):496-7.
  110. Schnabl B. Peroxisome proliferator-activated receptor-as emerging target in liver disease. Drug Dev Res. 2010; 71:106–111.
  111. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, Miura K, Kodama Y. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011; 41(7):683-6.
  112. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis - Crosstalk between the liver and gut. J Physiol. 2011; 590(Pt 3):447-58.
  113. Yan AW, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol. 2012;4(4):110-8.
  114. Hartmann P, Chen W, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012; 3:402.
  115. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Seki E, De Minicis S, Oesterreicher C, Taura K. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair. 2012; 5 Suppl 1:S17.
  116. Schnabl B, Brenner DA. Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. Gut. 2013; 62(3):335-6.
  117. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013; 29(3):264-70.
  118. Schnabl B. Transplanting a fibrogenic microbiota. Hepatology. 2014, 59(5):1660-1.
  119. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513-24.
  120. Jalan R, Fernandez J, Weist R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot , Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Ginès P. Bacterial Infections in Cirrhosis. A position statement based on the EASL Special Conference. J Hepatol. 2014; 60(6):1310-24.
  121. Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut and Liver. 2014, 8(3):237-241.
  122. Schnabl B. The Microbiome and the Liver. Gastroenterol Hepatol (N Y). 2014; 10(8):519-21.
  123. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: The gut microbiome and liver crosstalk. Alcohol Clin Exp Res. 2015; 39(5):763-75.
  124. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell and Mol Gastroenterol and Hepatol. 2015; 1(3):275–284.
  125. Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015; 9(8):1069-76.
  126. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015; 63(5):1272-84.
  127. Brenner DA, Paik YH, Schnabl B. Role of gut microbiota in liver disease. J Clin Gastroenterol. 2015; 49 Suppl 1:S25-7.
  128. Ho SB, Matheny M, Schnabl B. Changes in hospital admissions and mortality for complications of cirrhosis: implications for clinicians and health systems. Gut and Liver. 2016; 10(1):8-9.
  129. Nakamoto N, Schnabl B. Does the intestinal microbiota explain differences in the epidemiology of liver disease between East and West? Inflamm Intest Dis. 2016; 1(1):3-8.
  130. Schnabl B. Liver Capsule: Mechanisms of Alcoholic Hepatitis. Hepatology. 2016; 64(1):276.
  131. Fuchs M, Schnabl B. Editors' Introduction to the NAFLD and NASH Special Issue. Dig Dis Sci. 2016; 61(5):1211-3.
  132. Arroyo V, Moreau R, Kamath PS, Jalan R, Gines P, Nevens F, Fernandez J, To U, Garcia-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nature Reviews Disease Primers. 2016; 2:16041.
  133. Chen P, Miyamoto Y, Mazagova M, Lee K, Eckmann L, Schnabl B. Microbiota and alcoholic liver disease. Alcohol Clin Exp Res. 2016; 40(8):1791-2.
  134. Llorente C, Schnabl B. Fast-track clearance of bacteria from the liver. Cell Host Microbe. 2016; 20(1):1-2.
  135. Stärkel P, Schnabl B. Bidirectional communication between liver and gut during alcoholic liver disease. Semin Liver Dis. 2016; 36(4):331-339.
  136. Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and non-alcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016; 311(6): G1018-G1036.
  137. Brandl K, Schnabl B. The intestinal microbiota and NASH. Curr Opin Gastroenterol. 2017; 33(3):128-133.
  138. Hendrikx T, Schnabl B. Lamin deficiency in the liver sets the stage for NASH development in men. Cell and Mol Gastroenterol and Hepatol. 2017; 4(3):441-442.
  139. Boule LA, Ju C, Agudelo M, Parira T, Cannon A, Davis B, Eby J, Cresci G, Samuelson DR, Shukla P, Alrefai WA, Sureshchandra S, Pandey SC, Schnabl B, Curtis BJ, Wyatt TA, Choudhry MA, Kovacs EJ. Summary of the 2016 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol. 2018; 66:35-43.
  140. Hochrath K, Schnabl B. Check your microbiota when taking the drug. Hepatology. 2018; 67(1):18-20.
  141. Stärkel P, Leclercq S, de Timary P, Schnabl B. Intestinal dysbiosis and permeability: the ying and yang in alcohol dependence and alcoholic liver disease. Clin Sci (Lond). 2018 19; 132(2):199-212.
  142. Inamine T, Schnabl B. Immunoglobulin A, and Liver Diseases. Journal of Gastroenterology. 2018; 53(6):691-700.
  143. Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Research. 2018; 2(1):43-51.
  144. Hartmann P, Schnabl B. Risk factors for progression of NAFLD and treatment options for NAFLD in children. Clinical Liver Disease; 2018, 11(1):11-15.
  145. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018; 15(7):397-411.
  146. Chu H, Duan Y, Yang L, Schnabl B. Small Metabolites, Possible Big Changes—a Microbiota-centered View of Non-alcoholic Fatty Liver Disease. Gut. 2019; 68(2):359-370.
  147. Marrero I, Maricic I, Feldstein A, Loomba R, Schnabl B, Rivera-Nieves J, Eckmann L, Kumar V. Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. Frontiers Immunology. 2018; 9:2082.
  148. Brandl K, Hartmann P, Jih LJ, Pizzo DP, Schnabl B. Reply to: Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot? J Hepatol. 2018; 69(6):1400-1401.
  149. Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol. 2019; 17(2):218-230.
  150. Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease.  Journal of Gastroenterology. 2019; 54(3):209-217.
  151. Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcoholic liver disease J Hepatol. 2019; 70(2):260-272.
  152. Szabo G, Kamath PS, Shah VH, Thursz M, Mathurin P.  EASL-AASLD Joint Meeting Collaborators: Addolorato G, Bataller R, Burra P, Castera L, Cortez Pinto H, Diehl AM, Gao B, Gilmore SI, Hampe J, Jürgen R, Karin M, Krag A, Leon D, Leptak C, Louvet A, Lucey M, McClain C, Nagy L, Pageaux GP, Sanyal A, Schnabl B, Tiniakos D, Trautwein C, Tsukamoto H. Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. Hepatology. 2019; 69(5):2271-2283.
  153. Hendrikx T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. Journal of Internal Medicine. 2019; 286(1):32-40.
  154. Hartmann P, Chu H, Yi D, Schnabl B. Gut microbiota in liver disease: Too much is harmful, nothing at all is not helpful either. Am J Physiol Gastrointest Liver Physiol. 2019; 316(5): G563-G573.
  155. Zhou R, Fan X, Schnabl B. Role of the Intestinal Microbiome in Liver Fibrosis Development and New Treatment Strategies. Translational Research. 2019; 209:22-38.
  156. Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R , Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, Thursz M. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut. 2019; 69(4):764-780. PMCID: PMC7236084.
  157. Neuman MG, Seitz HK, French SW, Malnick S, Tsukamoto H, Cohen LB, Hoffman P, Tabakoff B, Fasullo M, Nagy LE, Tuma PL, Schnabl B, Mueller S, Groebner JL, Barbara FA, Yue J, Nikko A, Alejandro M, Brittany T, Edward V, Harrall K, Saba L, Mihai O. Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research. Biomedicines. 2020; 8(3). pii: E63. PMCID: PMC7148515.
  158. Jiang L, Schnabl B. Gut microbiota in liver disease: what do we know and what do we not know? Physiology (Bethesda). 2020; 35(4):261-274. PMCID: PMC7474259.
  159. Lang S, Schnabl B. Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future. Cell Host Microbe. 2020; 28(2):233-244. PMCID: PMC746784.
  160. Mendes BG, Schnabl B. From intestinal dysbiosis to alcohol-associated liver disease. Clin Mol Hepatol. 2020; 26(4):595-605. PMCID: PMC7641547.
  161. Lang S, Demir M, Schnabl B. Targeting pathobionts for the treatment of alcohol-associated liver disease. Liver Int. 2021; 41(1):239-240. PMCID: PMC7772232.
  162. Gao B, Emami A, Nath S, Schnabl B. Microbial products and metabolites contributing to alcohol-related liver disease. Mol Nutr Food Res. 2020; in press. PMCID: PMC7758187.
  163. Tranah TH, Edwards LA, Schnabl B, Shawcross DL. 'Recent Advances in Clinical Practice' - Targeting the Gut-Liver-Immune axis to treat Cirrhosis. Gut. 2020; in press. PMID33060124. PMCID pending.
  164. Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metabolism. 2020; in press. PMID33296678. PMCID pending.
  165. Jiang L, Stärkel P, Fan JG, Fouts DE, Bacher P, Schnabl B. The gut mycobiome: a novel player in chronic liver diseases. Journal of Gastroenterology. 2020; in press. PMID: 33151407. PMCID pending
  166. Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut Microbiome, Liver Immunology, and Liver Diseases. Cell Mol Immunol. 2020; in press. PMID33318628. PMCID pending.
  167. Hasan A, Hasan LK, Schnabl B, Greytak M, Yadlapati R. Microbiome of the Aerodigestive Tract in Health and Esophageal Disease. Dig Dis Sci. 2020; in press. PMID33236315. PMCID pending.
  168. Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-associated and Non-alcoholic Fatty Liver Disease. Semin Liver Dis. 2020; accepted.
  169. Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2020; accepted.
  170. Fairfied B, Schnabl B. Gut dysbiosis as a driver and target in alcohol-induced liver injury. J Hepatol Rep. 2020; accepted.
  171. Duan Y, Young R, Schnabl B. Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2021; accepted.
  172. Gao B, Chi L, Zhu Y, Shi X, Tu P, Li B,Yin J, Gao N, Shen W, Schnabl B. An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. Biomolecules. 2021; accepted.
  173. Hsu C, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol. 2021; accepted.

           Book Chapters

  1. Schnabl B. Metagenomic applications and the potential for understanding chronic liver disease. In Nelson KE, Editor. Metagenomics of the Human Body. Springer; 2010: 277-96.
  2. Brandl K, Schnabl B. Liver Disease: Interactions with the Intestinal Microbiota. In Luigi Nibali and Brian Henderson, Editors. The human microbiota and chronic disease – dysbiosis as a cause of human pathology. Wiley Blackwell; 2016: 339-349.
  3. Hartmann P, Schnabl B. Translocation of bacteria and bacterial products from the intestinal lumen in cirrhosis.  Role of microbiota, intestinal mucosal integrity and local immune function. In Vincente Arroyo and Mauro Bernardi, Editors. Systemic inflammation and organ failure in cirrhosis. The Acute-on-Chronic Liver Failure syndrome (ACLF). Elsevier; 2016: 35-41.
  4. Baeckhed F, Schnabl B, Li J. Metabolism and microbiota. In Kristin Wannerberger, Editor. Microbiome: The human microbiota in health and disease. Ferring International Center SA; 2019: 33-55.